Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients	Alcon	Completed	Travoprost 0.004%	1	C-12-009	King Khaled Eye Specialist Hospital (Riyadh)
A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)	Merck Serono	Terminated	Lutropin alfa	3b	EMR200061_506	King Abdulaziz University Hospital (Jeddah)
SPIMACO Biosimilar Insulin Phase III Study: Clinical Efficacy and Safety	SPIMACO	Terminated	Fastulin R / Normulin N	3	(version 1.4) Aug 2011	King Fahad Medical City (Riyadh)
"A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes "	Sanofi	Terminated	GLIMEPIRIDE-HOE490	3	GLIME_R_05809	King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh)
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study.	Servier	Terminated	Ivabradine	3	CL3-16257-083	King Fahad Medical City (Riyadh)
A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy	Roche	Terminated	Bevacizumab+ Capecitabine	3	MO22223	King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors.	Novartis	Completed	Everolimus	3b	CRAD001K24133	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants	Novartis	Completed	Meningococcal ACWY Conjugate Vaccine	3b	V59P23	King Fahad Medical City (Riyadh)
An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"	Novartis	Completed	TKI258 / Sorafenib	3	CTKI258A2302	King Faisal Specialist Hospital and Research Center (Riyadh)
Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)	Novartis	Completed	Nilotinib	3b	CAMN107E2401	King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital and Oncology Center (Jeddah)